InfiCure Bio is nominated in the category “Spin-off company of the year” at Umeågalan 2018.
Umeågalan will be held on November 8th and this is an event aimed at celebrating companies and entrepreneurs working for development and growth of the region.
The base of Inficure Bio is a unique preclinical model for studies of fibrosis together with the owners’ competence in the field of inflammation/fibrosis as well as in work with preclinical models.
Development of fibrosis in the model is spontaneous, seen in multiple organs (e.g. liver and kidney) and is preceded by chronic inflammation. This resembles many of the human condition that constitute important therapy segments eg chronic liver disease and chronic kidney disease.
The company’s preferred business model is to offer pharmaceutical companies to test their new anti-inflammatory/anti-fibrotic drugs in the unique preclinical model. The offer includes set-up, execution, analysis and reporting of results from the effect tests.